These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 29543887

  • 1. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
    Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T.
    PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
    [Abstract] [Full Text] [Related]

  • 2. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N, Okamoto M, Tsuji S, Endo Y, Takatani A, Shimizu T, Umeda M, Fukui S, Sumiyoshi R, Igawa T, Koga T, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Nakamura H, Origuchi T, Eguchi K, Ueki Y, Kawakami A.
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [Abstract] [Full Text] [Related]

  • 3. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC, Ho LY, Ma KM.
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [Abstract] [Full Text] [Related]

  • 4. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T, Yoshida S, Fujiki Y, Hata K, Kotani T, Takeuchi T.
    Arch Osteoporos; 2021 Feb 23; 16(1):39. PubMed ID: 33624165
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
    Tanaka I, Tanaka Y, Soen S, Oshima H.
    J Bone Miner Metab; 2021 May 23; 39(3):446-455. PubMed ID: 33211212
    [Abstract] [Full Text] [Related]

  • 6. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
    Mok CC, Ho LY, Leung SMT, Cheung HN, Chen SPL, Ma KM.
    Bone; 2021 May 23; 146():115902. PubMed ID: 33631355
    [Abstract] [Full Text] [Related]

  • 7. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 8. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov 15; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan 15; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 10. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 15; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 11. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Osteoporos Int; 2019 Jan 15; 30(1):241-249. PubMed ID: 30187112
    [Abstract] [Full Text] [Related]

  • 12. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y, Suzuki T, Kato H.
    Arch Osteoporos; 2017 Sep 21; 12(1):80. PubMed ID: 28936606
    [Abstract] [Full Text] [Related]

  • 13. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L, Vidal J, Carrasco JL, Muxi A, Portell E, Monegal A, Guañabens N, Peris P.
    Osteoporos Int; 2016 Jan 21; 27(1):405-10. PubMed ID: 26423406
    [Abstract] [Full Text] [Related]

  • 14. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr 21; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 15. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
    Kaji H, Kuroki Y, Murakawa Y, Funakawa I, Funasaka Y, Kanda F, Sugimoto T.
    Osteoporos Int; 2010 Sep 21; 21(9):1565-71. PubMed ID: 19921083
    [Abstract] [Full Text] [Related]

  • 16. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.
    Arch Dermatol; 2012 Mar 21; 148(3):307-14. PubMed ID: 22105813
    [Abstract] [Full Text] [Related]

  • 17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan 21; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 18. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec 21; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 19. Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.
    Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, Yamamoto Y, Iyoda M, Ryu K, Inaba T, Shibata T.
    J Bone Miner Res; 2019 Jun 21; 34(6):1014-1024. PubMed ID: 30690785
    [Abstract] [Full Text] [Related]

  • 20. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K.
    J Rheumatol; 2010 Jan 21; 37(1):141-8. PubMed ID: 19918047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.